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Abstract
Background: Squamous cell carcinoma (SCC) is one of the most common human cancers worldwide. In SCC,
tumour development is accompanied by an immune response that leads to massive tumour infiltration by
inflammatory cells, and consequently, local and systemic production of cytokines, chemokines and other mediators.
Studies in both humans and animal models indicate that imbalances in these inflammatory mediators are
associated with cancer development.
Methods: We used a multistage model of SCC to examine the involvement of elastase (ELA), myeloperoxidase
(MPO), nitric oxide (NO), cytokines (IL-6, IL-10, IL-13, IL-17, TGF-β and TNF-α), and neutrophils and macrophages in
tumour development. ELA and MPO activity and NO, IL-10, IL −17, TNF-α and TGF-β levels were increased in the
precancerous microenvironment.
Results: ELA and MPO activity and NO, IL-10, IL −17, TNF-α and TGF-β levels were increased in the precancerous
microenvironment. Significantly higher levels of IL-6 and lower levels of IL-10 were detected at 4 weeks following
7,12-Dimethylbenz(a)anthracene (DMBA) treatment. Similar levels of IL-13 were detected in the precancerous
microenvironment compared with control tissue. We identified significant increases in the number of GR-1+
neutrophils and F4/80+/GR-1- infiltrating cells in tissues at 4 and 8 weeks following treatment and a higher
percentage of tumour-associated macrophages (TAM) expressing both GR-1 and F4/80, an activated phenotype,
at 16 weeks. We found a significant correlation between levels of IL-10, IL-17, ELA, and activated TAMs and the
lesions. Additionally, neutrophil infiltrate was positively correlated with MPO and NO levels in the lesions.
Conclusion: Our results indicate an imbalance of inflammatory mediators in precancerous SCC caused by
neutrophils and macrophages and culminating in pro-tumour local tissue alterations.
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Introduction
Inflammatory responses play decisive roles in different
stages of tumour development, including initiation, pro-
motion, progression, invasion, and metastasis. The tumour
microenvironment, which is orchestrated by inflammatory
cells, affects malignant cells through the production of
cytokines, chemokines, growth factors, prostaglandins, re-
active oxygen species (ROS) and nitric oxide (NO) [1-5].
Sub-lethal levels of ROS and NO, which are produced by
activated neutrophils and macrophages, drive cancer de-
velopment by inducing DNA damage [6-8]. They also
stimulate cancer cell proliferation, assisting tumour es-
tablishment [5,9]. Myeloperoxidase (MPO), which is
abundantly expressed in neutrophils and to a lesser ex-
tent in monocytes and certain type of macrophages [10],
has been strongly correlated with different types of can-
cer progression due to its role in ROS generation
[2,9,11]. Additionally, the proteolytic enzyme elastase
(ELA) is also involved with carcinogenesis and metasta-
sis through degradation of the extracellular matrix, fa-
cilitating cancer invasion [12,13].
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Squamous cell carcinoma (SCC) is one of the most
common cancers in humans and typically arises from
mutated ectodermal or endodermal cells lining body
cavities. While SCC can occur in a large number of tis-
sues, cells in the skin are frequently associated with cel-
lular abnormalities in the basal layer of the epidermis
resulting from UV-damaged keratinocytes [14-16]. Al-
though immunosuppression is currently considered to
be a risk factor for SCC, inflammation is involved in
SCC establishment, and UV light has been demon-
strated to increase inflammatory infiltrates, which
enhances skin tumour growth [17,18]. In this manner,
CXCL8 has been suggested as an earlier biomarker for
SCC [19] because this chemokine, one of the most im-
portant neutrophil chemotactic and activating factors,
is related to angiogenesis, tumour growth and me-
tastasis [20]. However, other cytokines and che-
mokines that coordinate leukocyte migration to
inflammatory sites and cellular trafficking through
the lymph nodes and the spleen have been associated with
SCC development [20,21]. The two-stage 7,12-dimethyl-
benz(a)-anthracene (DMBA)/12-O-tetradecanoylphorbol-
13-acetate (TPA) skin carcinogenesis model, which triggers
the initiation and promotion steps, respectively, has
been commonly used to mimic squamous cell carcin-
oma, allowing for the investigation of several aspects
of SCC [22,23]. TPA/PMA tumour promotion is
based on protein kinase C (PKC) activation culmina-
ting in the release of reactive oxygen species (ROS)
[24,25].
Because inflammatory events have been implicated in
carcinogenesis and neutrophil infiltration is correlated
with some types of cancer metastasis [26,27], we used a
multistage model of SCC to examine the involvement of
ELA, MPO, NO, cytokines and inflammatory cells in
tumour development.
Methods
Mice
Eight-week-old female BALB/c mice were purchased
from the Bauru School of Dentistry, University of São
Paulo. Each mouse was housed in an isolated cage. Food
and water were provided ad libitum. The mice were
maintained on a 12-h light/12-h dark photocycle in a
controlled temperature environment and were quaran-
tined for a minimum of 1 week before treatment.
Groups of mice were randomly euthanised between
4 weeks and 16 weeks following 7,12-dimethylbenz-
anthracene (DMBA) (Sigma-AldrichW, St. Louis, MO,
USA) application. A total of 36 mice were used in the
study. All animal experiments were approved by the
Animal Research Ethics Committee of the Bauru School
of Dentistry, University of São Paulo.
DMBA/PMA-induced skin carcinogenesis
initiation-promotion experiments
The experimental group received DMBA and 12-O-
tetradecanoyl-phorbol-13-acetate (TPA) (Sigma-AldrichW)
as follows. Eight-week-old female mice were divided into
3 groups of three mice (at 4th, 8th and 16th weeks) each
and were topically treated with four doses of DMBA
(25 μg in 200 μl of acetone) and biweekly doses of TPA
(200 μl of a 10–4 M solution in acetone) for 16 weeks.
The experiment was performed 3 times. Papilloma and
carcinoma development were monitored every three days
throughout the experiment. Papillomas were charac-
terised by folded epidermal hyperplasia protruding from
the skin surface, and carcinomas were characterised as
endophytic tumours presenting as plaques with an ulcer-
ated surface. Experimental animals were cared for in
accordance with institutional guidelines. Untreated mice
were used as the control group. Samples were collected
at different time points after initiation and were pro-
cessed as described below. Lesions were initially identi-
fied macroscopically and subsequently identified through
histological diagnosis.
Measurement of tumour growth
Skin tumours were measured using a precision calliper
allowing discrimination to size modifications >0.1 mm.
Tumour volumes were measured the first day of treat-
ment and every week until the day that they were hu-
manely killed and the lesions were measured according
to followed: volume = 0.4 ab2, where a and b are the lar-
ger and smaller diameters, respectively [28].
Histological analysis
Tissue samples were collected from tumour sites and
fixed with 10% (v/v) formalin for 6 hours at room
temperature. The tissues were subsequently dehydrated
in ethyl alcohol followed by washes in xylol and were
then embedded in paraffin. Each sample was sectioned
into 5- to 7-μm-thick slices that were dried onto slides
and stained with hematoxylin and eosin.
Isolation of leukocytes
To characterise the leukocytes present at the tumour
site, biopsies of skin lesions from mice were collected
and incubated for 1 h at 37°C in RPMI 1640 medium
containing 50 μg/mL of a collagenase CI enzyme blend
(Boehringer Ingelheim Chemicals, Normandy Drive
Petersburg, VA, USA). The tissues were subsequently
dissociated for 4 min in RPMI 1640 (GIBCOW, Life
Technologies, Staley Road Grand Island, NY, USA) with
10% bovine foetal serum (GIBCOW, Life Technologies)
and 0.05% DNase (Sigma-AldrichW) using a Medimachine
(BD Biosciences, Qume Drive San Jose, CA, USA) cyto-
metry sample preparation system, according to the
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manufacturer’s instructions. The tissue homogenates were
filtered using a 30-μm cell strainer (Falcon; BD Bios-
ciences). Leukocyte viability was evaluated by Trypan blue
exclusion, and these cells were subsequently used for cell
activation and immunolabelling assays.
Antibodies (Abs) and flow cytometry analysis
For immunostaining, PE- and FITC-conjugated Abs
directed against CD11b (17A2), LY6G/GR-1+ (H129.19),
F4/80 (6F12) and the respective goat and rat isotype
controls were used (BD Biosciences). Intracellular IL-17
(BD Biosciences) in leukocytes obtained from lesions
and lymph nodes was detected using Cytofix/Cytoperm
and Perm/Wash buffer from BD Biosciences, according
to the manufacturer’s instructions. Briefly, the cells were
labelled with Abs directed against the cell surface anti-
gens. Following surface staining, the cells were fixed,
permeabilised, and stained with PE-labelled anti-mouse
IL-17 (MACS Miltenyi Biotech, Miltenyi Biotec GmbH,
Bergisch Gladbach, Germany) or the isotype control.
The samples were acquired on a FACSort flow cy-
tometer, and the data were analysed using CellQuest
software (BD Biosciences).
Immunofluorescence analysis and confocal microscopy
Slides for double immunofluorescence staining were
post-fixed with 4% paraformaldehyde and blocked with
protein-block assay diluent (BD Company). After wash-
ing with PBS, the slides were incubated with the primary
antibody, washed again, and incubated with the appro-
priate fluorochrome-conjugated (Texas Red or FITC)
secondary antibodies. After washing, the slides were
mounted using mounting medium with DAPI (Vector
LaboratoriesW, Burlingame, CA, USA) to stain the nu-
cleus and were then analysed by confocal microscopy.
Images were captured with a Leica TCS SPE confocal
laser system equipped with a 63 oil-immersion plan apo-
chromatic objective (1.3 CS) with differential interfer-
ence contrast. LAS AF 2.5.1 software was used for image
acquisition.
Cytokine assays
The tumour sample supernatants were obtained by dis-
aggregation through treatment with RPMI 1640 medium
containing 0.25% collagenase (Worthington Biochemical
Corporation, Lakewood, NJ, USA) and were frozen
at −80°C until analysis. The total protein concentration
was measured using a Quick StartTM Bradford Protein
assay kit (Bio-Rad, CA, USA). TNF-α, IL-6, IL-10 and
TGF-β levels in the samples were quantified using a
quantitative sandwich enzyme-linked immunosorbent
assay (ELISA) that employed commercial capture and
biotinylated detection antibodies (BD Pharmingen Corp.,
San Diego, CA), and the respective recombinant mouse
cytokines (diluted in PBS) as standards according to the
manufacturer’s instructions. IL-13 and IL-17 levels were
determined using an eBioscience kit (eBioscienceW,
San Diego, CA, USA) according to the manufacturer’s
instructions. The concentration of each cytokine was
dosed as pg/mL, and the results were normalised and
expressed as mg/protein.
Myeloperoxidase (MPO) and elastase (ELA) activities
MPO and ELA activities in the samples were assessed
after obtaining tissue supernatants by disaggregation
through treatment with RPMI 1640 (Gibco) medium
containing 0.25% collagenase (Worthington Biochemical
Corporation) as described previously [29].
Nitric oxide production
To detect NO in lesions or skin samples, nitrite (NO-2)
production was measured in the supernatant samples
using the Griess method [29]. Briefly, 50 μL of super-
natant samples were incubated with an equal volume of
Griess reagent at room temperature. The absorbance
was measured on a plate scanner (Spectra Max 250; Mo-
lecular Devices, Sunnywale, California, USA) at 540 nm.
The NO-2 concentration was determined using a stand-
ard curve for NaNO2 at a concentration range from 1 to
200 μM.
Statistical analysis
The results are expressed as the mean ± SD, and sta-
tistical analysis was performed using unpaired Student’s
t-tests to compare each experimental group with the
control group and a one-way ANOVA followed by
Tukey’s test to compare all groups (GraphPad software 4).
p ≤ 0.05 was considered to indicate statistical significance.
Results
The appearance of chemically induced papillomas is ac-
companied by increased neutrophil infiltration
Papillomas were found in 100% of DMBA/TPA-treat-
ment mice seven weeks after carcinogenic induction
(data not shown). The greatest number of papillomas
was found at 16 weeks (10.7 ± 2 lesions) (Figure 1A and
1G). Lesions found at this time were significantly more
extensive (since 4.5 until >40 mm) than those found
during the 4th and 8th weeks (Figure 1B). Histological
analysis revealed polymorphonuclear cells in the superfi-
cial layers of the epithelium at 4 weeks (Figure 1D), with
pronounced inflammatory cell presence and intense epi-
thelial cell mitotic activity at 8 weeks (Figure 1F). In-
tense inflammatory infiltrate and mitotic activity and
epithelial islet formation were observed at 16 weeks after
DMBA/TPA treatment (Figure 1H). We identified poly-
morphonuclear and mononuclear inflammatory cells in
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different layers of the skin tissue after DMBA treatment
(Figure 1D, 1F and 1H).
Inflammatory mediators levels during the establish-
ment of SCC.
Because tissue damage triggered by inflammatory
mediators is associated with cancer establishment,
we evaluated MPO and ELA activity in the chemically
treated tissue samples (Figure 2). The results showed
increased MPO activity at 4 weeks (1348 ± 334.7 units/mg),
8 weeks (2975 ± 1231 units/mg) and 16 weeks (1187 ±3
21.8 units/mg) following DMBA/TPA treatment in
comparison with control mice (159.9 ± 12.3 units/mg)
(Figure 2A).
NO levels in the tissue samples were significantly
higher after chemical treatment compared to the control
group (Figure 2B). Interestingly, the highest levels of NO
were detected in the 8-week group (1460 ± 215.1μM)
(Figure 2B), which was also verified by MPO activity
(Figure 2A).
ELA activity increased as a function of the time of treat-
ment. The 4-week (9.8 ± 2.4 units/mg), 8-week (22.4 ±
17.2 units/mg) and 16-week (54.6 ± 9.9 units/mg) groups
all had ELA activities that were significantly higher than
that of the control group (2.19±0.2 units/mg) (Figure 2C).
Cytokine levels in the tumour microenvironment during
the establishment of SCC
To evaluate cytokine expression during the develop-
ment and establishment of experimental SCC, we ana-
lysed IL-6, IL-10, IL-13, IL-17, TNF-α and TGF-β levels
in the lesion tissues (Figure 3). At 16 weeks following
DMBA treatment, levels of all of these cytokines with
Figure 1 Squamous cell carcinoma induced by DMBA/TPA in mice. SCC mice were treated according to a chemical carcinogenic protocol
using DMBA and TPA for 16 weeks. Papilloma incidence (A) and tumor volume (B) were determined in SCC mice. Each value represents mean ±
SEM of 9 different mice. *P<0.05, **P<0.01 and *** P< 0.001. Panels C, E and G are representative photomicrographs of dorsal tissue from SCC
mice. Haematoxylin and eosin staining of skin tissue sections from BALB/c mice 4(D), 8(F) and 16 (H) weeks after chemical carcinogenesis. Data
are from one experiment that is representative of three independent experiments (n = 9 mice per group). Arrows indicate inflammatory cells.
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the exception of IL-6 had significantly increased in the
treated tissues compared with control skin (Figure 3A-
3F). Among the treated groups, significantly higher
levels of IL-10, IL-17, TNF-α and TGF-β were detected
in the 16 week group compared with the 4 and 8 week
groups (Figures 3B, 3D, 3E and 3F). Although IL-13,
TNF-α and TGF-β levels increased in all groups
compared with control samples (Figures 3C, 3E and 3F),
IL-10 levels decreased at 4 weeks after DMBA treatment
(620.8 ± 68 pg/mg) and increased to levels higher
than that of the control group at 8 weeks (9876 ±
1120 pg/mg) (Figure 3B). The highest levels of IL-6 were
detected at 4 weeks (14403 ± 3026 pg/mg) compared to
the 8 week (4193 ± 1065 pg/mg), 16 week (1673 ±
309.8 pg/mg) and control groups (474.9 ± 11.1 pg/mg)
(Figure 3A).
In agreement with these data, a significant increase in
cytokine levels was detected during SCC development
compared with the untreated group (week 0). We veri-
fied that the highest levels of the cytokines IL-10, IL-17,
TNF-α and TGF-β were present at 16 weeks (Figure 3).
Determination of macrophages and neutrophils
infiltrating squamous cell carcinoma lesions
To determine if the increased cytokine levels recruited
increased numbers of inflammatory cells, we evaluated
the number of leukocytes in the lesions (Figure 4A). As
expected, the number of leukocytes infiltrating the
lesions increased over time, increasing from 0.7 ±
0.06x106 in the 4th week to 0.9 ± 0.13x106 in the 8th
week and 1.5 ± 0.3x106 in the 16th week (Figure 4A).
However, significant differences were only detected be-
tween the 16-week group and the 4- and 8-week groups
(p<0.05, Figure 4A).
We next analysed the inflammatory infiltrates, asses-
sing the presence of neutrophils and macrophages in
chemically treated tissues from the mice at 4, 8 and
16 weeks following DMBA treatment (Figure 4B-4C).
To determine the neutrophil and macrophage pheno-
types present in the tissues infiltrates, the percentage
of cells expressing GR-1 and F4/80 were evaluated by
flow cytometry (Figure 4B). Neutrophils, as character-
ised by a GR-1+/F4/80- phenotype, were increased at
4 (34.6 ± 2.5%) and 8 weeks (55.9 ± 3.2%) compared
with 16 weeks (27.3 ± 3.8%). Macrophages were also
present at higher percentages in the 4th (47.7 ± 4.9%)
and 8th (35.6 ± 3.2%) week compared to the 16th week
(24.3 ± 6.1%) (Figure 4B). However, macrophages exhi-
biting an activated phenotype and characterised by
expression of both GR-1 and F4/80 were present at a
significantly higher concentration at 16 weeks (57.7 ±
0.9%) than at 4 (20.5 ± 5.7%) or 8 weeks (26.5 ± 5.9%)
following DMBA/TPA treatment (Figure 4B). Representa-
tive photomicrographs show immunofluorescence stain-
ing for 4 weeks (Figure 4C-D), 8 weeks (Figure 4E-F) and
16 weeks (Figure 4 G-H) following DMBA application.
Although the milieu of cytokines and oxidative com-
pounds might influence SCC establishment and prog-
ression, the lesions only showed correlation with ELA,
IL-10 and IL-17 (Table 1).
Neutrophil tissue infiltration was positively and signifi-
cantly correlated with MPO and NO levels in the epithe-
lial tissues (Table 2). While we did not find any
correlation between the presence of neutrophils and
papillomas or tumour lesions, macrophages were posi-
tively and significantly correlated with both lesions
(Tables 2 and 3). In addition, macrophages were posi-
tively and significantly correlated with ELA activity and
Figure 2 MPO, NO and ELA levels in the tumour
microenvironment. MPO (A), NO (B) and ELA (C) levels were
analyzed in the tumor and control untreated tissue as described in
the methods and materials section. Results are expressed as the
mean ± SEM from each individual mouse analyzed. *P<0.05,
**P<0.01 and *** P< 0.001.
Gasparoto et al. Journal of Inflammation 2012, 9:46 Page 5 of 11
http://www.journal-inflammation.com/content/9/1/46
IL-10 and IL-17 levels in epithelial tissues between 0 and
16 weeks (Table 3).
Discussion
Cancer is a complex, multistage process characterised
by molecular alterations regulated by both genetic and
epigenetic mechanisms [30]. Because DNA lesions and
methylation states are influenced by oxidative species
catalysed by MPO, it is logical to assume that an asso-
ciation exists between this enzyme and cancer initia-
tion [30-32]. Polymorphisms in the MPO gene promoter
region are associated with a reduced risk of cancer
[33-35]. Here, we demonstrate the presence of neutro-
phils and activated macrophages during the develop-
ment of chemically induced squamous cell carcinoma.
This cell infiltration was accompanied by myeloperoxi-
dase and elastase activity and the presence of nitric
oxide. Both myeloperoxidase (MPO) and elastase (ELA)
are enzymes that are abundantly secreted by activated
neutrophils, a mechanism that helps these cells to de-
fend against aggression [10,36]. MPO dimeric alpha-
heme halo peroxidase present in azurophilic granules
makes up approximately 5% of the dry weight of the
neutrophil [37]. Although MPO is correlated with a
better prognosis in different types of tumours such
as breast cancer [34,38-41], the majority of studies
have shown an important role for MPO in cancer
progression [2,9,11,31]. It was shown that TPA-
stimulated mouse neutrophils exhibit DNA damage
resulting from hydrogen peroxide-induced breaks [42].
In support of this finding, we found MPO to be signifi-
cantly more active in chemically treated mice than in
control mice, and we found a positive correlation with
neutrophil infiltration.
Both MPO and ELA appeared to contribute to tissue
and extracellular matrix degradation, enhancing cancer
development by destroying natural barriers against me-
tastasis [43,44]. Several studies have also described elas-
tinolytic enzyme production by human and rodent
mammary tumour cells that facilitates their dissemin-
ation [10,45,46]. ROS-mediated oxidative tissue damage
and ROS-mediated upregulation of the gene expression
responsible for recruitment of inflammatory cells can
both inhibit tumour growth and support the metastatic
growth of tumour cells [5,24,25].
Figure 3 Cytokine levels in the tumour microenvironment. IL-6 (A), IL-10 (B), IL-13 (C), IL-17 (D), TNF-α (E) and TGF-β (F) levels were
analyzed by ELISA. Results are expressed as the mean ± SEM from each individual mouse analyzed (n=9 mice per group). *P<0.05, **P<0.01
and *** P < 0.001.
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Figure 4 Inflammatory infiltrates in mouse squamous cell carcinoma. The total number of leukocytes (A) and the number of cells
expressing GR1 and F4/80 (B) were determined during the 4th (4W), 8th (8W) and 16th (16W) weeks after DMBA protocol. Results are expressed
as the mean ± SEM from each individual mouse analyzed (n=9 mice per group). *P< 0.05 and *** P< 0.001. Representative photomicrograph of
GR1+ (green), F4/80+ (red) and IL-17+ cells (red) infiltrating tumour lesions. Representative tumour is shown. Blue, DAPI.
Table 1 Correlation between lesions and inflammatory
mediators during the chemical-induced squamous cell
carcinoma development
Lesions
Correlation (r)2 P Pearson r
ELA 0.9761 0.0120* 0.9880
IL-10 0.9799 0.0101* 0.9899
IL-17 0.9309 0.0352* 0.9648
Neutrophils 0.0066 0.9186 0.08144
Macrophages 0.9846 0.0154* 0.9695
*Statistically significant difference comparing lesions appearance with elastase
(ELA) activity, IL-10 and IL-17 levels, and neutrophils or macrophage infiltration.
Table 2 Correlation between neutrophils and
inflammatory mediators during the chemical-induced
squamous cell carcinoma development
Neutrophils
Correlation (r)2 P Pearson r
MPO 0.9211 0.0430* 0.9761
NO 0.9717 0.0142* 0.9858
ELA 0.0509 0.7743 0.2257
Papiloma 0.0123 0.8888 0.1112
Tumor 0.1436 0.8802 -0.1198
*Statistically significant difference comparing neutrophils infiltration with
myeloperoxidase (MPO) activity, nitric oxide (NO) level, elastase (ELA) activity,
and number of papilloma and tumor lesions.
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Although three types of ELA have been characterised
in mammals, only neutrophil elastase (NE) is able to de-
grade insoluble elastin and hydrolyse other extramatrix
proteins, including fibronectin, proteoglycans, and type
IV collagen [13,47,48]. NE has also been shown to in-
crease cancer cell malignancy through mechanisms that
are still unclear [13]. We detected high ELA activity at 4
weeks after DMBA/TPA treatment that persisted until
16 weeks and increased as the lesions grew. It is possible
that ELA sources such as macrophages, neutrophils, and
cancer cells change during chemically induced SCC de-
velopment. Our data showed that macrophage but not
neutrophil infiltration was correlated with ELA activity
in the lesions. This result should be further elucidated in
the future.
Because our results indicated the involvement of in-
flammation during chemically induced SCC develop-
ment, and a key molecular link between inflammation
and tumour promotion and progression is the NF-kB
signalling pathway, which is activated by many proin-
flammatory cytokines [49,50], we analysed cytokine pro-
duction in the tumour microenvironment. IL-6 was
significantly enhanced at 4 weeks after DBMA/TPA
treatment, while IL-10 levels were lowest in these
samples (Figure 4). IL-6 and TNF-α are the major pro-
inflammatory cytokines implicated in inflammation-
associated carcinogenesis, enhancing tumour cell growth
[51,52]. Because the highest levels of IL-6 occurred at
the onset of SCC induction, it is possible that this cyto-
kine plays a role in cancer establishment in our model.
IL-6 has also been shown to inhibit the extrinsic and in-
trinsic apoptotic pathways of skin cells, supporting the
hypothesis that it may contribute to tumourigenesis [53].
Although IL-6 has previously been connected with squa-
mous cell carcinoma bone invasion, which occurs during
late stages of the disease [54], the highest concentra-
tion of this cytokine was detected at the beginning
of DMBA-treatment. TNF-α also has also been pro-
posed to contribute to squamous cell carcinoma tumour
initiation and bone invasion [54] by stimulating the pro-
duction of genotoxic molecules that can lead to DNA
damage and mutations, such as NO [55], which is
increased in all treated groups (Figure 2B) [56-58].
Levels of IL-13 were also diminished in chemically trea-
ted skin after the 4th week (Figure 3C). Because IL-13
can negatively regulate anti-tumour immunity modula-
ting NKT cell function, it may cooperate in cancer deve-
lopment [59].
The dual functions of IL-10 in antitumor immunity
and immunoregulation have been recognized for some
time [60]. In our study, the low levels of IL-10 detected
in tumour initiation phase could be contributed to mu-
rine SCC development. IL-10 has been shown to modu-
late apoptosis and suppress angiogenesis and enhance
the production of tumor-toxic molecules (e.g., nitric
oxide) [61,62] and low levels of this cytokine could be
favour tumor development. In fact, IL-10 deficient mice
were more sensitive to DMBA/TPA induced papilloma
[63]. In the promotion and progression phase, we
detected a significant enhancement in IL-10 at 8 and
16 weeks after DMBA/TPA treatment. An IL-10 auto-
crine or paracrine loop might play an important role in
tumour cell proliferation and survival through the upre-
gulation of antiapoptotic genes such as BCL-2 or BCL-
XL [64-66]. In addition, IL-10 inhibits secretion of the
proinflammatory cytokines by CD4+ T cells and impairs
CD8+ T cells response, whereas tumor clearance can be
enhanced in the absence of IL-10 [67,68].
In the 16th week, the cytokines IL-10, IL-17, TGF-β
and TNF-α were detected at the highest overall level,
creating a chronic inflammation cytokine milieu that
may lead to antitumour immunity eradication and acce-
lerated tumour progression. TGF-β enhances tumour in-
vasion and, with TNF-α, affects stromal cells, facilitates
angiogenesis, and impairs NK cells, CD8+ T cells and
macrophage activity against tumours [58,69,70]. Add-
itionally, TGF-β-induced inflammation in precancerous
epidermal squamous lesions has been shown to require
IL-17 [71]. IL-17 has also been associated with different
types of cancer and may be expressed by tumour- asso-
ciated macrophages and neutrophils to a lesser degree
[69,72,73]. We found significant percentages of GR-1+
macrophages in the tumour tissue at 16 weeks
(Figure 4B), and this macrophage phenotype has been
reported to express IL-12p40 and iNOS [74]. However,
GR1+F4/80+ cells have been reported to have negative
effects on tumour protection [75]. Neutrophils and GR-
1- macrophages were the predominant cell type in lesion
tissue at 4 and 8 weeks (Figure 4B), and GR-1- macro-
phages are poor producers of NO [74]. These data sug-
gest that MPO and NO were primarily produced by
neutrophils at the start of SCC development and estab-
lishment (Table 2). However, ELA seemed to be
Table 3 Correlation between F4/80+GR1+macrophages
and inflammatory mediators during chemical-induced
squamous cell carcinoma development
Macrophages
Correlation (r)2 P Pearson r
ELA 0.9895 0.0053** 0.9947
IL-10 0.9140 0.0439* 0.9561
IL-17 0.9915 0.0043** 0.9957
Papiloma 0.9665 0.0169* 0.9831
Tumor 0.9114 0.0453* 0.9547
*Statistically significant difference comparing macrophages GR1+F4/80+
infiltration with elastase (ELA) activity, IL-10 and IL-17 levels, and number of
papilloma and tumor lesions.
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primarily produced by activated macrophages along with
IL-10 and IL-17, correlating with lesion appearance
(Table 3).
In summary, the data presented here are in according
with previous studies [2-9], which show that inflamma-
tory mediators activate the remodeling of the tumor
microenvironment through recruitment of leukocytes.
The data presented here expand previous observation's
by demonstrate that DMBA-induced inflammatory med-
iators are produced in the initial phase of carcinogenesis
by activated neutrophils and macrophages. These find-
ings may have broad implications besides providing a
better insight into the mechanisms involved in DMBA-
induced carcinogenesis. Increase of inflammatory media-
tors such as NO, active MPO and ELA, which are up-
regulated in response to chronic inflammation, can
increase mutation rates because induce DNA damage
and genomic instability, in addition to enhancing the
proliferation of mutated cells [2-9]. These events are
associated with tumor initiation and progression, sug-
gesting that inflammatory mediators may play an im-
portant role in initiation and promotion phase of SCC
development. These findings represent a significant step
towards in carcinogenesis.
Conclusion
Our results suggest that activated neutrophils and macro-
phages are involved in inflammatory mediator production
in tumour microenvironment. These cells may drive some
immunity-related skin tissue damage and support cancer
establishment.
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